Consilium news
- Home/
- News & insights/
- Consilium news/
- Consilium Strategic Communications supports MiroBio on successful $97...
5th July 2022
Consilium Strategic Communications supports MiroBio on successful $97 million Series B financing
London, 5 July 2022, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have supported MiroBio on its recently announced $97 million Series B financing to develop checkpoint receptor agonists for the treatment of autoimmune diseases.
The financing round was led by Medicxi with significant participation from new investors, OrbiMed and Monograph Capital, and existing Series A investors, Oxford Science Enterprises, Samsara BioCapital, SR One and Advent Life Sciences.
MiroBio is entering clinical stage development with checkpoint receptor agonist antibodies, a new class of therapy which aims to restore immune balance and treat autoimmune diseases. The Company has also created I-ReSToRE (REceptor Selection and Targeting to Reinstate immune Equilibrium), a unique discovery platform to build a pipeline of checkpoint receptor agonists. I-ReSToRE combines the proprietary Checkpoint Atlas™ of receptor expression and function, sophisticated antibody discovery processes and advanced bioinformatics to enable a precision medicine approach to autoimmune disease.
The proceeds from the financing will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials, as well as advance its pre-clinical pipeline and further develop the I-ReSToRE platform.
"We congratulate the MiroBio team on this significant Series B financing. The support from such a high calibre group of international investors is a testament to the strength of MiroBio’s science and team. It also points to the potential of immune checkpoint agonists, an emerging and innovative class of therapeutic, to restore immune balance in patients with autoimmune diseases. We are proud to have worked with MiroBio’s team to amplify the news with key international stakeholders."
Mary-Jane Elliott
Managing Partner of Consilium Strategic Communications"The Series B financing gives MiroBio the resources to demonstrate the unique potential of our checkpoint agonists for autoimmune patients and strengthens our transatlantic investor base and board. We are pleased to share this important news with key audiences internationally and thank Consilium for helping us achieve this"
Eliot Charles
Chairman of MiroBioThe Consilium team advising MiroBio on the financing included Mary-Jane Elliott, Jessica Hodgson, Tracy Cheung, Melissa Gardiner, Stella Lempidaki and Jessica Pilling.
-Ends-
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in financial and corporate communications and investor relations focused on the healthcare sector. Consilium's team, based in both Europe and US, provides strategic, long-term PR and IR advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes, international media management, transactions and healthcare stakeholder challenges. Consilium has established deep knowledge and expertise across all areas of the global healthcare sector through broad involvement in representing international clients spanning the Fortune 500, FTSE 100, FTSEurofirst 300 and FTSE 250, through to discrete specialist reputation management projects.
For more information please see
About MiroBio
MiroBio is a private biotechnology company formed out of Oxford University and backed by a strong group of international investors: Medicxi, OrbiMed, Oxford Science Enterprises, Samsara BioCapital, SR One, Advent Life Sciences and Monograph.
The Company is entering clinical stage development with a new class of checkpoint agonist antibodies to restore immune balance. MiroBio has developed I-ReSToRE, a proprietary discovery platform including the Checkpoint Atlas™ to generate multiple checkpoint agonist candidates for the treatment of autoimmune diseases.
The platform combines cutting-edge receptor mapping with epitope and antibody engineering. It is the product of more than 15 years’ foundational research from Oxford University into identifying and triggering checkpoint receptors to deliver safe, efficacious medicines to restore immune homeostasis.
Visit our website for more information:
